ATE359281T1 - Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren - Google Patents
Tricyclic antitumor komponenten als farnesyl protein transferase inhibitorenInfo
- Publication number
- ATE359281T1 ATE359281T1 AT01968188T AT01968188T ATE359281T1 AT E359281 T1 ATE359281 T1 AT E359281T1 AT 01968188 T AT01968188 T AT 01968188T AT 01968188 T AT01968188 T AT 01968188T AT E359281 T1 ATE359281 T1 AT E359281T1
- Authority
- AT
- Austria
- Prior art keywords
- protein transferase
- transferase inhibitors
- farnesyl protein
- tricyclic
- antitumor components
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22918300P | 2000-08-30 | 2000-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359281T1 true ATE359281T1 (de) | 2007-05-15 |
Family
ID=22860141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01968188T ATE359281T1 (de) | 2000-08-30 | 2001-08-28 | Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020198216A1 (enExample) |
| EP (1) | EP1313725B1 (enExample) |
| JP (1) | JP2004513885A (enExample) |
| KR (1) | KR20030034161A (enExample) |
| CN (1) | CN100384837C (enExample) |
| AR (1) | AR033680A1 (enExample) |
| AT (1) | ATE359281T1 (enExample) |
| AU (2) | AU8845101A (enExample) |
| BR (1) | BR0113675A (enExample) |
| CA (1) | CA2420673A1 (enExample) |
| CO (1) | CO5640109A2 (enExample) |
| DE (1) | DE60127846T2 (enExample) |
| EC (1) | ECSP034494A (enExample) |
| ES (1) | ES2284686T3 (enExample) |
| HK (1) | HK1054548B (enExample) |
| HU (1) | HUP0302942A3 (enExample) |
| IL (1) | IL154528A0 (enExample) |
| MX (1) | MXPA03001849A (enExample) |
| NO (1) | NO20030918L (enExample) |
| NZ (1) | NZ524246A (enExample) |
| PE (1) | PE20020486A1 (enExample) |
| PL (1) | PL361103A1 (enExample) |
| RU (1) | RU2293734C9 (enExample) |
| SK (1) | SK2292003A3 (enExample) |
| TW (1) | TWI268280B (enExample) |
| WO (1) | WO2002018368A1 (enExample) |
| ZA (1) | ZA200301545B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| EE05417B1 (et) * | 2001-03-14 | 2011-06-15 | Bristol-Myers Squibb Company | Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias |
| JP2005531488A (ja) * | 2001-10-09 | 2005-10-20 | ザ・ユニバーシティ・オブ・シンシナティ | 甲状腺癌を処置するためのｅｇｆ受容体阻害剤 |
| EP1448268A2 (en) * | 2001-11-30 | 2004-08-25 | Schering Corporation | Use of an farnesyl protein transferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer |
| JP2005515201A (ja) * | 2001-12-03 | 2005-05-26 | シェーリング コーポレイション | 癌の処置におけるｆｐｔインヒビターおよび少なくとも２つの抗腫瘍性剤の使用 |
| US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US20040014744A1 (en) * | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| EP1606285A4 (en) * | 2003-03-27 | 2009-03-18 | Lankenau Inst Medical Res | NEW IDO HEMMER AND APPLICATION PROCEDURES |
| EP1628631A2 (en) * | 2003-06-05 | 2006-03-01 | Achkar, Charles C. | Methods of treating hyperproliferative cell disorders |
| BRPI0411250A (pt) * | 2003-06-09 | 2006-08-29 | Samuel Waksal | método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular |
| ES2235611B2 (es) * | 2003-07-25 | 2006-07-16 | Universidade De Santiago De Compostela | Metodo cuantitativo para la deteccion de yesotoxinas en productos pesqueros basado en la activacion que producen en las fosfodiesterasas. |
| BRPI0413384A (pt) * | 2003-08-07 | 2006-10-17 | Schering Corp | inibidores da proteìna farnesil transferase como agentes antitumores |
| US7592466B2 (en) | 2003-10-09 | 2009-09-22 | Abbott Laboratories | Ureas having antiangiogenic activity |
| MY138124A (en) * | 2004-12-21 | 2009-04-30 | Schering Corp | Novel farnesyl protein transferase inhibitors as antitumor agents |
| RU2361587C1 (ru) * | 2008-02-14 | 2009-07-20 | Михаил Владимирович Кутушов | Лекарственное средство для лечения онкологических заболеваний |
| CA2730190A1 (en) * | 2008-07-14 | 2010-01-21 | Queen's University At Kingston | Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer |
| WO2020258211A1 (en) * | 2019-06-28 | 2020-12-30 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| IL98572A (en) * | 1990-06-22 | 1995-07-31 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene, piperidylidene and piperazine compositions an methods of use |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| PE92098A1 (es) * | 1996-07-31 | 1998-12-31 | Schering Corp | N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo |
| US6071907A (en) * | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US5925648A (en) * | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
| CA2354774C (en) * | 1998-12-18 | 2009-05-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
-
2001
- 2001-08-27 AR ARP010104082A patent/AR033680A1/es unknown
- 2001-08-28 HU HU0302942A patent/HUP0302942A3/hu unknown
- 2001-08-28 IL IL15452801A patent/IL154528A0/xx unknown
- 2001-08-28 CN CNB01818121XA patent/CN100384837C/zh not_active Expired - Fee Related
- 2001-08-28 TW TW090121201A patent/TWI268280B/zh active
- 2001-08-28 WO PCT/US2001/026792 patent/WO2002018368A1/en not_active Ceased
- 2001-08-28 PE PE2001000865A patent/PE20020486A1/es not_active Application Discontinuation
- 2001-08-28 MX MXPA03001849A patent/MXPA03001849A/es active IP Right Grant
- 2001-08-28 KR KR10-2003-7003012A patent/KR20030034161A/ko not_active Ceased
- 2001-08-28 AU AU8845101A patent/AU8845101A/xx active Pending
- 2001-08-28 AU AU2001288451A patent/AU2001288451C1/en not_active Ceased
- 2001-08-28 BR BR0113675-5A patent/BR0113675A/pt not_active IP Right Cessation
- 2001-08-28 SK SK229-2003A patent/SK2292003A3/sk not_active Application Discontinuation
- 2001-08-28 NZ NZ524246A patent/NZ524246A/en unknown
- 2001-08-28 PL PL01361103A patent/PL361103A1/xx unknown
- 2001-08-28 AT AT01968188T patent/ATE359281T1/de not_active IP Right Cessation
- 2001-08-28 RU RU2003108865/04A patent/RU2293734C9/ru not_active IP Right Cessation
- 2001-08-28 HK HK03105016.6A patent/HK1054548B/en not_active IP Right Cessation
- 2001-08-28 EP EP01968188A patent/EP1313725B1/en not_active Expired - Lifetime
- 2001-08-28 JP JP2002523486A patent/JP2004513885A/ja active Pending
- 2001-08-28 DE DE60127846T patent/DE60127846T2/de not_active Expired - Fee Related
- 2001-08-28 US US09/940,811 patent/US20020198216A1/en not_active Abandoned
- 2001-08-28 ES ES01968188T patent/ES2284686T3/es not_active Expired - Lifetime
- 2001-08-28 CA CA002420673A patent/CA2420673A1/en not_active Abandoned
-
2003
- 2003-02-25 ZA ZA200301549A patent/ZA200301545B/xx unknown
- 2003-02-26 EC EC2003004494A patent/ECSP034494A/es unknown
- 2003-02-27 CO CO03017118A patent/CO5640109A2/es active IP Right Grant
- 2003-02-27 NO NO20030918A patent/NO20030918L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE359281T1 (de) | Tricyclic antitumor komponenten als farnesyl protein transferase inhibitoren | |
| ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
| AU2001240658A1 (en) | Farnesyl protein transferase inhibitor combinations with camptothecin compounds | |
| DE60101323D1 (de) | Tricyclische proteinkinasehemmer | |
| EP1324985A4 (en) | PRENYL PROTEIN TRANSFERASE INHIBITORS | |
| ATE293622T1 (de) | Farnesyl protein transferase inhibitoren | |
| DE60121038D1 (de) | Inline sichtvorrichtung | |
| IS6571A (is) | Samsett lyfjameðferð | |
| AU2001239275A1 (en) | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives | |
| AU2001246478A1 (en) | Farnesyl protein transferase inhibitor combinations with taxane compounds | |
| AU2001252147A1 (en) | Farnesyl protein transferase inhibitor combinations | |
| IL163673A0 (en) | Farnesyl protein transferase inhibitors as antitumor agents | |
| DE602004018332D1 (de) | Neue farnesylproteintransferaseinhibitoren als antitumormittel | |
| DK1339695T3 (da) | Farnesyltransferase-inhibitorer | |
| NO20012961D0 (no) | Trisykliske farnesylproteintransferase-inhibitorer | |
| ZA200705126B (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
| IS6358A (is) | Farnasýl transferasa latar | |
| ATE371655T1 (de) | Farnesyl-protein-transferaseinhibitoren | |
| DE60132440D1 (de) | Kombinationschemotherapie | |
| DK1165069T3 (da) | Synergistisk antitumorpræparat | |
| FI20000049A0 (fi) | Sovitelma LVI-putkiston yhteydessä |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |